Product Pathways
BCP0001 GDC-0941

1.The IC50 values of GDC0941 for the inhibition of phosphorylation of Ser473 on AKT in IGROV-1 cells following 2-

BCP0002 GDC0449(Vismodegib)

GDC-0449 is a more potent and specific synthetic oral SMO(signaling transducer Smoothened)inhibitor,with 0.003&mic

BCP0003 GDC-0879

GDC-0879 is a highly selective, novel potent, orally bioavailable B-Raf inhibitor in various in vitro and cell-bas

BCP0004 Gefitinib

Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). S

BCP0005 Gemcitabine Hydrochloride

Gemcitabine(dFdC) is a new pyrimidine antimetabolite which has shown good clinical activity in pancreatic, breast,

BCP0006 GSK1904529A

GSK1904529A is a reversible, ATP-competitive inhibitor and has enzyme-inhibitor binding values against IGF-IR and

BCP0007 GSK461364

GSK461364, a selective i.v. thiophene amide inhibitor of PLK1, induced selective G2/M arrest followed by apoptosis

BCP0008 GSK690693

GSK690693 is an aminofurazan-derived inhibitor of Akt kinases with potential antineoplastic activity. It binds to

BCP0009 Abiraterone(CB-7598)

ABIRATERONE(CB-7598), a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently

BCP0010 ABT-263(Navitoclax)

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of

第一页 1 2 3 4 5 6 7 8 9 10 下10页 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.